Connect with us
Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

News

The Law Offices of Frank R. Cruz Announces Investigation of Neovasc, Inc (NVCN) on Behalf of Investors

gbafNews28

The Law Offices of Frank R. Cruz announces an investigation of Neovasc, Inc (Neovasc or the Company) (NASDAQ: NVCN) on behalf of investors concerning the Companys possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

Neovascs Reducer is a medical device that treats refractory angina by altering blood flow in the hearts circulatory system. In December 2018, the Company filed a Q-Sub submission to the U.S. Food and Drug Administration (FDA) that contained safety and efficacy results from Neovascs clinical studies, as well as supporting data from peer-reviewed journals.

On February 20, 2019, the Company announced that, despite Breakthrough Device Designation, the FDA review team recommended collection of further pre-market blinded data prior to Pre-Market Approval (PMA) submission.

On November 1, 2019, Neovasc announced that it would submit a PMA application for the Reducer without gathering further evidence, against the FDAs recommendation. The Company claimed that the clinical evidence already available will be sufficient to not further delay the availability of this Breakthrough medical device for the treatment of U.S. patients.

On October 28, 2020, before the market opened, Neovasc announced that an FDA advisory committee voted overwhelmingly against issuing a reasonable assurance of effectiveness and on whether the relative benefits outweighed the relative risks. The panel echoed concerns previously raised by the FDA about the lack of sufficient data.

On this news, the Companys share price fell $0.77, or 42%, to close at $1.06 per share on October 28, 2020, thereby injuring investors.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

If you purchased Neovasc securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to info@frankcruzlaw.com, or visit our website at www.frankcruzlaw.com. If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

The Law Offices of Frank R. Cruz, Los Angeles

Frank R. Cruz, 310-914-5007

fcruz@frankcruzlaw.com

www.frankcruzlaw.com

Advertisement
Editorial & Advertiser disclosure

Call for Entries

Global Banking and Finance Review Awards Nominations 2022
2022 Awards now open. Click Here to Nominate

Newsletters with Secrets & Analysis. Subscribe Now

Recommended

Global Banking & Finance Review® is a leading financial portal and Print Magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management. Copyright © 2010-2021 GBAF Publications Ltd - All Rights Reserved.